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Objective. The purpose of our study was to evaluate the utility of the American
College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS) sono-
graphic final assessment system and palpation-guided fine-needle aspiration (FNA)
for evaluation of palpable breast lesions. Methods. Our computerized database
identified 160 palpable lesions of the breast in which follow-up palpation-guided
FNA, targeted sonography, and pathologic confirmation were performed. We used
BI-RADS sonographic data on all lesions. The sensitivity, specificity, accuracy, positive
predictive value, and negative predictive value of malignancy were calculated for
sonography and palpation-guided FNA. Two-sample binomial proportion tests were
used as the statistical analysis (P < .05). Results. The FNA results were defined as
benign, atypical cells, suspicious for malignancy, malignancy, and insufficiency. The
sensitivity, specificity, accuracy, positive predictive value, and negative predictive value
were 90.9%, 82.7%, 84.3%, 57.7%, and 97.2%, respectively, on sonography and
75.8% to 90.9%, 82.7% to 98.4%, 84.3% to 94.4%, 57.7% to 92.6%, and
93.9% to 97.2% on FNA. There was no statistically significant difference for sensi-
tivity and negative predictive value between the two examinations. Conclusions.
The diagnostic accuracy of sonography was similar to that of palpation-guided FNA
for not missing the malignancy. Clinical application of FNA results can be difficult,
especially when the result is insufficiency or atypical cells. Moreover, FNA is invasive
and overlaps other procedures. Therefore, we conclude that sonography can replace
palpation-guided FNA for diagnosis of palpable lesions of the breast when the BI-
RADS sonographic final assessment system is used appropriately. Key words: breast,
neoplasms; breast neoplasms, diagnosis; breast neoplasms, sonography.
Received January 9, 2006, from the Department of
Diagnostic Radiology, Research Institute of
Radiological Science, Yonsei University College of
Medicine, Seoul, Korea (J.Y.K., E.-K.K., K.K.O.); and
Departments of Diagnostic Radiology (J.Y.K.),
General Surgery (H.-L.P.), and Pathology (J.-Y.K.),
Pochon Cha University College of Medicine, Seoul,
Korea. Revision requested March 5, 2006. Revised
manuscript accepted for publication April 25, 2006.
Address correspondence to Eun-Kyung Kim,
MD, Department of Diagnostic Radiology,
Research Institute of Radiological Science, Yonsei
University College of Medicine, 134 Shinchon-
Dong, Seodaemun-gu, Seoul 120-752, Korea.
E-mail: ekkim@yumc.yonsei.ac.kr
Abbreviations
BI-RADS, Breast Imaging Reporting and Data System;
FNA, fine-needle aspiration; NPV, negative predictive
value; PPV, positive predictive value
alpable lesions of the breast are common occur-
rences at breast clinics. The “triple test” (physical
examination, mammography, and fine-needle
aspiration [FNA]) was initially described in 1975
for evaluation of palpable breast lesions.1 After that,
many reports supported the usefulness of the triple
test.2–5 In 1996, a modified triple test replaced mammog-
raphy with sonography for palpable breast masses in
younger women.6
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With improvement of imaging equipment
and techniques, some reports have shown that
negative mammographic and sonographic
results make the invasive procedure superflu-
ous.7–9 Nevertheless, for diagnosing palpable
breast lesions, many overlapping examinations
are still done, including palpation-guided FNA,
imaging studies, and pathologic confirmation.
Until now, application of the American College
of Radiology’s Breast Imaging Reporting and
Data System (BI-RADS) has been limited primar-
ily to mammography. Recently, the American
College of Radiology introduced application of
the BI-RADS to sonography.10 To our knowledge,
little evidence exists about the application of the
BI-RADS sonographic final assessment system to
palpable breast lesions. Therefore, this study was
designed to evaluate the effectiveness of the BI-
RADS sonographic final assessment system and
to reconsider the diagnostic algorithm for palpa-
ble breast lesions.
Materials and Methods
Our computerized database identified 160 palpa-
ble lesions of the breast on physical examination in
which palpation-guided FNA, targeted sonogra-
phy, and pathologic confirmation were performed.
We reviewed data from May 1, 2002, through
October 1, 2004. This period included 408 palpable
lesions of the breast (384 female patients).
Palpation-guided FNA was done in 188 cases.
Among the total cases reviewed, this study includ-
ed 160 palpable breast lesions (151 patients) that
underwent the modified triple test (physical exam-
ination, sonography, and FNA) and pathologic
confirmation. The mean age of the patients was 34
years, with a range of 14 to 73 years. The palpable
lesions ranged in size from 6 to 65 mm (mean, 23.3
mm). We excluded simple cysts on sonography.
Mammography
Mammographic examinations in this study were
performed with dedicated mammography units
(Senographe DMR, GE Healthcare, Milwaukee,
WI). Standard craniocaudal and mediolateral
oblique views were routinely obtained, and addi-
tional mammographic views were obtained as
needed. Mammographic examinations were
performed on 132 patients. The remaining 28
patients did not undergo mammographic exam-
inations because of very young age and loss of
outside mammography services. Each study was
interpreted by an expert breast imager (J.Y.K.).
The location of palpable abnormalities was indi-
cated by metallic BB markers or clinical notes.
Sonography
We routinely performed a focused sonographic
examination that targeted the area of clinical
concern. The sonographic examination was per-
formed by the same radiologist (J.Y.K.) who inter-
preted the mammogram, usually immediately
after reviewing the mammogram. Therefore,
each sonographic examination was performed
with full knowledge of the clinical and mammo-
graphic findings. Each patient was evaluated
with real-time sonography using an HDI 3000 or
HDI 5000 system (Philips Medical Systems,
Bothell, WA) with a linear 5- to 12-MHz probe.
Routine studies did not include color or power
Doppler sonography.
Each lesion was classified according to the BI-
RADS sonographic protocol. Category 1 was nor-
mal, and category 2 was a benign finding such as
a cyst or a nodule with intense homogeneous
hyperechogenicity. We used many suspicious
sonographic findings, including irregular shape,
complex echogenicity, posterior shadowing,
spiculated margins, microlobulated margins,
nonparallel orientation, microcalcifications, and
duct extension. If any suspicious finding was pre-
sent, the lesion was categorized as 4. When a
mass had 3 or more suspicious findings, it was
categorized as 5. If a mass detected on sonogra-
phy was not categorized as 2, 4, or 5, it classified
as category 3.11 Interpretation of sonography was
performed prospectively. Fine-needle aspiration
results were interpreted by an experienced breast
cytopathologist (J.-Y.K.).
Fine-Needle Aspiration
In our hospital, FNA is an office-based procedure
with palpation guidance. This procedure was
performed by an experienced breast surgeon
(H.-L.P.) with a 20-gauge needle and an aspirator.
This procedure was done after imaging studies
(mammography, sonography, or both), not dis-
turbing the interpretation of the images.
Histopathologic Confirmation
Pathologic confirmations were done with a sono-
graphically guided 14-gauge automated gun
biopsy (37 cases), 11- or 8-gauge vacuum-assisted
biopsy (37 cases), or excision (86 cases). The sur-
geon chose the biopsy method, especially with
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the presentation of benign characteristics in the
modified triple test and mammography. In 74
patients who chose to undergo needle biopsy,
a short-term follow-up study with sonography
was recommended for the first 2 years. There-
after, we performed scheduled screening follow-
up, with a follow-up duration of about 12 to 32
months (mean, 26 months).
Statistics
The sensitivity, specificity, accuracy, positive pre-
dictive value (PPV), and negative predictive
value (NPV) of malignancy were calculated for
sonography and palpation-guided FNA. Two-
sample binomial proportion tests were used for
the statistical analysis (P < .05) to compare
sonography and palpation-guided FNA.
Results
Histopathologic Confirmation
There were 33 malignant and 127 benign results
(Table 1). Table 2 shows the age distribution of
the patients studied. Patients younger than 30
years constituted 38.8% of the patients in this
study. The percentage of malignancy increased
according to age.
Mammography and Sonography
Among these 160 lesions, mammography was
available for 132 cases (99 benign cases and 33
malignant cases). In 4 cases, both mammo-
graphic and sonographic findings were negative.
Three cases showed a heterogeneously dense
breast, and the remaining breast was extremely
dense. In all of them, the findings were con-
firmed as negative by excision despite negative
imaging findings because of a high degree of
clinical suspicion or patient anxiety. The patho-
logic results were fibrocystic change (2 cases),
fibroadenoma (1 case), and periductal chronic
inflammation (1 case). Five (15.2%) of 33 malig-
nancies had negative mammographic findings,
even with the presence of a metallic BB marker
on mammography.
Analysis of Cytologic Examination and
Sonography
The results of the palpation-guided FNA were
defined as benign, atypical cells, suspicious for
malignancy, malignancy, and insufficiency. The
analysis of palpable lesions on sonography used
the BI-RADS sonographic final assessment sys-
tem. Interpretations were classified as categories
1 through 5.
The cytologic results of 4 cases with normal
mammographic and sonographic findings were
1 atypical cell, 1 insufficiency, and 2 benign
findings.
There were 11 cancers (61.1%) among the 18
patients in whom the palpable abnormality
showed atypical cells or was suspicious for
malignancy on FNA. Ten (90.9%) of 11 cancers
were classified as category 4 on sonography; the
remaining cancer was classified as category 3
(Table 3). Seven (38.9%) of 18 patients received a
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Table 1. Results of 160 Pathologic Examinations of
Palpable Breast Lesions
Lesion n
Malignancy 33
Invasive ductal carcinoma, NOS 29
Invasive ductal carcinoma, atypical medullary 1
Malignant phyllodes tumor 2
Ductal carcinoma in situ 1
Benign 127
Fibroadenomas 68
Fibroadenomatous hyperplasia 13
Benign phyllodes tumors 11
Fibrocystic changes 9
Adenosis tumors 3
Intraductal papillomas 3
Lactating adenomas 3
Duct ectasia 3
Periductal chronic inflammation 3
Fibrosis 1
Florid papillomatosis 1
Nodular adenosis 1
Sclerosing adenosis 1
Sclerosing lobular hyperplasia 1
Sclerosing papilloma 1
Ductal hyperplasia 1
Hamartoma 1
Intraductal hyperplasia 1
Benign inflammation 1
Biphasic tumor 1
DCIS indicates ductal carcinoma in situ; and NOS, not other-
wise specified.
Table 2. Percentage of Malignancy According to Age Distribution
Patient Age, y No. of Cases Malignancy, % (n)
10–19 8 0 (0/8)
20–29 54 3.7 (2/54)
30–39 52 11.5 (6/52)
40–49 25 44 (11/25)
50–59 18 61.1 (11/18)
60–69 2 100 (2/2)
70–79 1 100 (1/1)
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diagnosis of a benign condition in the area of the
palpable abnormality despite atypical cells or
suspicion of malignancy on FNA. Among these 7
cases, 5 (71.4%) were scored as category 3 on
sonography (Table 3).
There were 2 (11.8%) cancers among 17 patients
in whom the palpable abnormality showed
insufficiency on FNA (Table 4). Each was clas-
sified as category 4 on sonography. Fifteen
(88.2%) of 17 patients received a diagnosis of
a benign condition in the area of the palpable
abnormality. Among these 15 cases, 13
(86.7%) were classified as category 1, 2, or 3
on sonography. 
Sonographic BI-RADS Assessment of Palpable Breast Lesions
Table 3. Sonographic Categorization and Pathologic Results for Atypical Cells and Suggestion of Malignancy
on FNA
Case Age, y Cytologic Results Sonographic Category Pathologic Results
1 48 Atypical cells 4 IDC, NOS
2 28 Atypical cells 4 IDC, NOS
3 40 Atypical cells 4 IDC, NOS
4 44 Atypical cells 4 IDC, NOS
5 56 Suspicious for malignancy 4 IDC, NOS
6 44 Suspicious for malignancy 4 IDC, NOS
7 35 Suspicious for malignancy 4 IDC, NOS
8 46 Suspicious for malignancy 4 IDC, NOS
9 61 Suspicious for malignancy 4 IDC, NOS
10 54 Suspicious for malignancy 4 IDC, NOS
11 53 Suspicious for malignancy 3 IDC, NOS
12 22 Atypical cells 1 Fibroadenoma
13 43 Atypical cells 3 Intraductal papilloma
14 26 Atypical cells 4 Sclerosing papilloma
15 42 Atypical cells 3 Intraductal papilloma
16 31 Atypical cells 3 Fibroadenoma
17 23 Suspicious for malignancy 4 Benign phyllodes tumor
18 33 Suspicious for malignancy 3 Intraductal papilloma
IDC indicates invasive ductal carcinoma; and NOS, not otherwise specified.
Table 4. Sonographic Categorization and Pathologic Results for Insufficiency on FNA
Case Age, y Sonographic Category Pathologic Results
1 28 3 Fibrocystic change
2 42 4 Periductal chronic inflammation
3 38 1 Fibrocystic change
4 48 4 IDC, NOS
5 22 3 Fibroadenomatous hyperplasia
6 53 3 Ductal hyperplasia
7 35 3 Fibroadenoma
8 35 3 Fibroadenoma
9 30 3 Fibroadenoma
10 29 3 Fibroadenoma
11 47 3 Florid papillomatosis
12 53 3 Fibrocystic change
13 20 3 Fibroadenoma
14 55 4 Duct ectasia
15 56 2 Fibroadenoma
16 43 3 Fibrosis
17 73 4 IDC, NOS
IDC indicates invasive ductal carcinoma; and NOS, not otherwise specified.
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Statistics
When atypical results from the cytologic exami-
nations were classified as negative, and insuffi-
cient samples were classified as positive or
negative or excluded, the sensitivity, specificity,
accuracy, PPV, and NPV were calculated (Table
5). When atypical results from the cytologic
examinations were classified as positive, and
insufficient samples were classified as positive or
negative or excluded, the sensitivity, specificity,
accuracy, PPV, and NPV were also calculated
(Table 5). When the palpable breast lesions on
sonography were interpreted according to the
BI-RADS sonographic final assessment, the sen-
sitivity, specificity, accuracy, PPV, and NPV were
calculated (Table 5). There was no statistical sig-
nificant difference for sensitivity and NPV
between the two examinations (P > .05; Table 5).
Discussion
With improvements in technology and careful
real-time evaluation, sonography is emerging as
an important diagnostic tool in young women
and an adjunctive method to mammography in
older women. Moreover, negative results of com-
bined studies, including mammography and
sonography, show a nearly 100% NPV for palpa-
ble breast lesions.7–9,12,13
In our hospital, many women with palpable
breast lesions evaluated with the triple or modi-
fied triple test have chosen pathologic confirma-
tion rather than imaging follow-up. Although a
recent study suggested that palpable noncalci-
fied solid breast masses with benign morpho-
logic characteristics on mammography and
sonography could be managed similarly to non-
palpable BI-RADS category 3 lesions, with short-
term follow-up,14 pathologic confirmation was
chosen for benign-looking masses because of
patient anxiety, clinician concern, or both. As a
result, many procedures overlapped for diagno-
sis and treatment of the breast lesions. In this
study, 188 (46.1%) of 408 palpable breast lesions
were evaluated with palpation-guided FNA. One
hundred sixty (85.1%) of the 188 lesions also
underwent pathologic confirmation. Such an
overlap of diagnostic procedures increases the
patient’s cost burden and may cause unneces-
sary discomfort.
In this study, 160 palpable breast lesions under-
went physical examination, palpation-guided
FNA, sonography, and confirmative biopsy or
surgery. Many palpable breast lesions were
found to be benign (79.38%), in concordance
with previous reports15,16 of about 79.4% benign
conditions in palpable breast lesions.
We compared sonography and many combined
FNA results. The sensitivity, specificity, accuracy,
PPV, and NPV were 90.9%, 82.7%, 84.3%, 57.7%,
and 97.2%, respectively, on sonography and
75.8% to 90.9%, 82.7% to 98.4%, 84.3% to 94.4%,
57.7% to 92.6%, and 93.9% to 97.2% on palpation-
guided FNA (Table 5). There was no statistically
significant difference for sensitivity and NPV
between the two examinations. Although in some
combined FNA results, specificity, accuracy, and
PPV were superior to those of sonography, it is
impossible to adjust these complex FNA results
in practical patient care. Also, in the objective of
not missing malignancy, sensitivity and NPV are
most important. Our study revealed no statistical
differences between FNA and sonography for
sensitivity and NPV (P > .05).
When cytologic results revealed insufficiency,
atypical cells, and suspicion of malignancy,
sonographic categorization provided good
guidance for managing palpable abnormalities.
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Table 5. Comparison of Sonography With FNA Cytologic Examination for Test Outcomes
FNA
Atypical Cells Are Classified as Negative Atypical Cells Are Classified as Positive
Insufficiency Insufficiency Insufficiency Insufficiency
Classified as Classified as Insufficiency Classified as Classified as Insufficiency
Outcome Sonography Positive Negative Excluded Positive Negative Excluded
Sensitivity, % 90.9 81.8 75.8 80.6 90.9 84.8 90.3
Specificity, % 82.7 86.6 98.4* 98.2* 82.7 94.5* 93.8*
Accuracy, % 84.3 85.6 93.8* 94.4* 84.3 92.5* 93*
PPV, % 57.7 61.4 92.6* 92.6* 57.7 80* 80*
NPV, % 97.2 94.8 93.9 94.8 97.2 96 97.2
*Statistically significant compared with results of sonography (P < .05).
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In this study, when the palpable abnormality was
characterized as having atypical cells or as being
suspicious for malignancy on FNA, 10 (90.9%) of 11
cancers were classified as category 4 on sonography.
Of the 18 cases in which FNA results were reported
as atypical cells or suspicion of malignancy, 7 had
benign conditions. Of these 7 cases, 5 (71.4%) were
classified as category 1 or 3 on sonography, indicat-
ing the possibility of false-positive cytologic results.
When the palpable abnormality showed insufficient
results on FNA, 2 (100%) of 2 cancers were classified
as category 4 on sonography.
Among the 160 palpable breast lesions in our
study, mammography was available for 132 cases
(99 benign cases and 33 malignant cases). About
15% (5/33 cases) of malignancies were mammo-
graphically occult, similar to findings in other
reports.17,18 These 5 cases had heterogeneously
dense breast tissue. There were 4 negative results
on mammography and sonography. All 4 cases
had heterogeneously or extremely dense breasts,
and all 4 were confirmed by excision despite neg-
ative imaging findings because of a high degree of
clinical suspicion or patient anxiety. The cytologic
results of these 4 cases were 1 atypical cell, 1 insuf-
ficiency, and 2 benign findings. The confirmatory
diagnoses of these cases were benign conditions
(2 fibrocystic changes, 1 fibroadenoma, and 1
periductal chronic inflammation). Although small
in number, our results support other studies in
which the NPV of negative mammographic and
sonographic findings was 100%.7–9,12,13 Moreover,
despite assessment by an experienced cytopathol-
ogist, FNA cytologic examination was not a reli-
able diagnostic method.
There were several limitations in our study.
First, the period of imaging follow-up (12–32
months) was insufficient in some cases. We
selected for the methods of pathologic confirma-
tion a 14-gauge automated gun, 11- or 8-gauge
vacuum assisted biopsy, and surgery. Although
many reports have shown a high level of accura-
cy with image-guided needle biopsy,19–24 contin-
uous imaging follow-up is needed. However,
there were no malignancies discovered at exci-
sion or during follow-up of benign lesions.
Second, our study was based on examination of
the data by breast specialists (an expert surgeon
and an expert radiologist skilled in breast imag-
ing). These data therefore may not be repro-
ducible in other institutions. Third, our data
group was a little small; therefore, further investi-
gation with a larger data set is needed.
Many palpable breast lesions, even those with
demonstrably benign findings, have been
removed by vacuum-assisted needle excision or
surgical excision because of patient anxiety,
physician concern, or both. We found that the
application of the BI-RADS sonographic final
assessment system to palpable breast lesions
was similar to FNA except for some combined
FNA applications. The application of FNA results
can be difficult, especially when the result is
insufficiency and atypical cells. Moreover, FNA 
is invasive and overlaps other procedures.
Therefore, we conclude that sonography can
replace palpation-guided FNA for diagnosis of
palpable lesions of the breast when sonographic
examinations are done meticulously.
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